MAP2K7 and acute myeloid leukemia: MEK inhibition as a combination strategy in addition to the standard “7 + 3” (clinical trial NCT02049801) or azacitidine and venetoclax (clinical trial NCT04487106) is currently being investigated for relapsed or refractory AML cases in several clinical trials [41].